3/7/2023-Unusual Options Activity In NSC
$NSC – Bearish flow noted in Norfolk Southern (217.50 -4.92) with 1,692 puts trading, or 1.8x expected. The Put/Call Ratio is 3.65, while ATM IV is up over 1 point on the day. Earnings are expected on 04/25.
Similar Posts
1/22/2024-Unusual Options Activity In WOLF
Wolfspeed, Inc. is an American developer and manufacturer of wide-bandgap semiconductors, focused on silicon carbide and gallium nitride materials and devices for power and radio frequency applications such as transportation, power supplies, power inverters, and wireless systems.
1/6/2023-Unusual Options Activity In PTON
Peloton Interactive, Inc. is an American exercise equipment and media company based in New York City. The company’s products are stationary bicycles, treadmills, and indoor rowers equipped with Internet-connected touch screens that stream live and on-demand fitness classes through a subscription service.
11/06/2024 -Unusual Options Activity In Tempus AI Inc (TEM)
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer.
Unusual Options Activity In Chevron (CVX)
3427 $CVX JUN 20th 2025 160.00 PUTS BOUGHT@ 5.2 vs Open Interest of 2655 for a total of $1787240 on the BEAR side
10/16/2024 -Unusual Options Activity In Cisco (CSCO)
Cisco Systems, Inc. is an American multinational digital communications technology conglomerate corporation headquartered in San Jose, California.
7/21/2023-Unusual Options Activity In IMGN
ImmunoGen, Inc. is a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company’s potent cell-killing agents attached as a “payload”. The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
